menu
    • menu

    Company profile for Beactica

    NEW Drugs in Dev: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Beactica is a speci ologies to evaluate the interaction of molecules in order to generate novel therapeutics. We believe in our ability to improve patients’ lives through our passion for science. With informed and creative minds we innovate novel small molecule modulators to become next-generation breakthrough therapies for life-threatening conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BeacticaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Beactica AB Virdings allé 2 754 50 Uppsala
    Telephone
    Telephone
    +46 (0)18 56 08 80
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.beactica.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/beactica-ab
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Beactica Holds First MPA Meeting On Development Of BEA-17
    Beactica Holds First MPA Meeting On Development Of BEA-17

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/beactica-conducts-first-advisory-meeting-with-the-swedish-medical-products-agency-regarding-the-development-of-bea-17-302576676.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share
    Beactica's TEAD programme selected for late-breaking research presentation
    Beactica's TEAD programme selected for late-breaking research presentation

    14 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/beactica-therapeutics-tead-programme-selected-for-late-breaking-research-presentation-at-the-aacr-annual-meeting-2024-302061530.html

    PR NEWSWIRE
    14 Feb 2024
    Share Share
    Beactica Therapeutics to present breakthrough in YAP-TEAD programme
    Beactica Therapeutics to present breakthrough in YAP-TEAD programme

    16 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/beactica-therapeutics-to-present-breakthrough-in-yaptead-programme-at-the-hippo-pathway-drug-development-summit-2023-301825604.html

    PR NEWSWIRE
    16 May 2023
    Share Share
    Beactica to present update on LSD1 programme at the AACR Annual Meeting 2023
    Beactica to present update on LSD1 programme at the AACR Annual Meeting 2023

    11 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/beactica-therapeutics-to-present-update-on-lsd1-programme-at-the-aacr-annual-meeting-2023-301794233.html

    PR NEWSWIRE
    11 Apr 2023
    Share Share
    Beactica and Oscotec mutually agree to conclude oncology collaboration
    Beactica and Oscotec mutually agree to conclude oncology collaboration

    04 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/beactica-therapeutics-and-oscotec-mutually-agree-to-conclude-oncology-collaboration-301789278.html

    PR NEWSWIRE
    04 Apr 2023
    Share Share
    Beactica receives FDA Orphan Drug Designation for BEA-17 for glioblastoma
    Beactica receives FDA Orphan Drug Designation for BEA-17 for glioblastoma

    01 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/beactica-therapeutics-receives-fda-orphan-drug-designation-for-bea-17-for-the-treatment-of-glioblastoma-301735895.html

    PR NEWSWIRE
    01 Feb 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search